Group items tagged

American Society of Clinical Oncology Meeting 2006.

Association between plasma 25-hydroxyvitamin D and breast cancer risk. Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, Shane E, Terry MB, Desai M, Teitelbaum SL, Neugut AI, Santella RM. Cancer Prev Res (Phila Pa). 2009 Jun;2(6):598-604. Epub 2009 May 26. PMID: 19470790 In summary, these results add to a growing body of evidence that adequate vitamin D stores may prevent breast cancer development. Whereas circulating 25-OHD levels of >32 ng/mL are associated with normal bone mineral metabolism, our data suggest that the optimal level for breast cancer prevention is ≥40 ng/mL. Well-designed clinical trials are urgently needed to determine whether vitamin D supplementation is effective for breast cancer chemoprevention.

Yeudall WA, Miyazaki H. Chemokines and squamous cancer of the head and neck: targets for therapeutic intervention? Expert Rev Anticancer Ther. 2007 Mar;7(3):351-60. PMID: 17338654 [PubMed - in process]

"The clinical potential for a liver-protective supplement in cancer care is significant, as I've observed in many years of integrative medical practice," writes Dr. Keith Block, ICT editor. "Several chemotherapy drugs, as well as many of the other drugs cancer patients take, have extremely problematic liver toxicities. With this exclusive edition, the scientific community will have a resource to guide and inspire further research on this very interesting herbal medicine."